Skip to main content
TipRanks
Go Ultimate75% OFF

10x Genomics (TXG) Stock Statistics & Valuation Metrics

1,308 Followers

Total Valuation

10x Genomics has a market cap or net worth of $7.23B. The enterprise value is $11.32B.

Market Cap
$7.23B
Enterprise Value
$11.32B

Share Statistics

10x Genomics has 121,455,315 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
121,455,315
Owned by Insiders
2.21%
Owned by Institutions
85.61%

Financial Efficiency

10x Genomics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -12.34%.

Return on Equity (ROE)
-0.05
Return on Assets (ROA)
-0.04
Return on Invested Capital (ROIC)
-12.34%
Return on Capital Employed (ROCE)
-0.12
Revenue Per Employee
545.69K
Profits Per Employee
-36.96K
Employee Count
1,178
Asset Turnover
0.62
Inventory Turnover
3.53

Valuation Ratios

The current PE Ratio of 10x Genomics is -106.38. 10x Genomics’s PEG ratio is 0.23.

PE Ratio
-106.38
PS Ratio
10.86
PB Ratio
8.63
Price to FCF
71.65
Price to Operating Cash Flow
72.57
PEG Ratio
0.23

Income Statement

In the last 12 months, 10x Genomics had revenue of 642.82M and earned -43.54M in profits. Earnings per share was -0.35.

Revenue
642.82M
Gross Profit
443.88M
Operating Income
-110.89M
Pretax Income
-39.91M
Net Income
-43.54M
EBITDA
3.91M
Earnings Per Share (EPS)
-0.35

Cash Flow

In the last 12 months, operating cash flow was 99.70M and capital expenditures -5.93M, giving a free cash flow of 93.77M billion.

Operating Cash Flow
99.70M
Free Cash Flow
93.77M
Free Cash Flow per Share
0.72

Dividends & Yields

10x Genomics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
1.40%
Earnings Yield
-0.93%

Stock Price Statistics

Beta
1.73
52-Week Price Change
246.07%
50-Day Moving Average
73.92
200-Day Moving Average
42.90
Relative Strength Index (RSI)
36.72
Average Volume (3m)
3.38M

Important Dates

10x Genomics upcoming earnings date is Feb 17, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 17, 2027
Ex-Dividend Date
―

Financial Position

10x Genomics as a current ratio of 4.46, with Debt / Equity ratio of 19.81%

Current Ratio
4.46
Quick Ratio
4.09
Debt to Market Cap
0.04
Net Debt to EBITDA
-80.90
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, 10x Genomics has paid 3.64M in taxes.

Income Tax
3.64M
Effective Tax Rate
-0.09

Enterprise Valuation

10x Genomics EV to EBITDA ratio is 139.50, with an EV/FCF ratio of 66.42.

EV to Sales
10.07
EV to EBITDA
139.50
EV to Free Cash Flow
66.42
EV to Operating Cash Flow
62.47

Balance Sheet

10x Genomics has $575.68M in cash and marketable securities with $75.79M in debt, giving a net cash position of $499.89M billion.

Cash & Marketable Securities
$575.68M
Total Debt
$75.79M
Net Cash
$499.89M
Net Cash Per Share
$4.12
Tangible Book Value Per Share
$5.91

Margins

Gross margin is 71.88%, with operating margin of -11.67%, and net profit margin of -10.84%.

Gross Margin
71.88%
Operating Margin
-11.67%
Pretax Margin
-10.53%
Net Profit Margin
-10.84%
EBITDA Margin
7.22%
EBIT Margin
0.24%

Analyst Forecast

The average price target for 10x Genomics is $74.15, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$74.15
Price Target Upside
34.85% Upside
Analyst Consensus
Moderate Buy
Analyst Count
15
Revenue Growth Forecast
-3.62%
EPS Growth Forecast
16.67%

Scores

Smart Score
1
AI Score
57